2011 Scrip 100: On the drug lag and serving Japan
This article was originally published in Scrip
The Democratic Party of Japan has taken an axe to many areas of public spending, but the country's medicines regulator has emerged relatively unscathed. In fact, the PMDA continues to increase its headcount to help cut the delay in delivering novel medicines to Japanese patients, the agency's Dr Tatsuya Kondo and Dr Hideo Utsumi tell Ian Haydock.
You may also be interested in...
Japan approval for BTK inhibitor marks new indication but in a small niche market, while another clearance may help extend Latuda's commercial life.
Novel antibody-drug conjugate receives approval in Japan for second-line breast cancer, providing another push to Japanese firm’s strategic plan to build up its oncology operations.
Collaboration with fundraising Tokyo-based venture builds mid-sized firm's interest in cell-based therapies in a highly supportive regulatory environment.